Literature DB >> 25263085

Comparison of objective criteria and expert visual interpretation to classify benign and malignant hilar and mediastinal nodes on 18-F FDG PET/CT.

Phan Nguyen1, Manoj Bhatt, Farzad Bashirzadeh, Justin Hundloe, Robert Ware, David Fielding, Aravind S Ravi Kumar.   

Abstract

BACKGROUND AND
OBJECTIVE: There is widespread adoption of FDG-PET/CT in staging of lung cancer, but no universally accepted criteria for classifying thoracic nodes as malignant. Previous studies show high negative predictive values, but reporting criteria and positive predictive values varies. Using Endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) results as gold standard, we evaluated objective FDG-PET/CT criteria for interpreting mediastinal and hilar nodes and compared this to expert visual interpretation (EVI).
METHODS: A retrospective review of all patients with lung cancer who had both FDG-PET/CT and EBUS-TBNA from 2008 to 2010 was performed. Scan interpretation was blinded to histology. Patients from 2008/2009 were used for the prediction set. The validation set analysed patients from 2010. Objective FDG-PET/CT criteria were SUVmax lymph node (SUVmaxLN), ratio SUVmaxLN/SUVmax primary lung malignancy, ratio SUVmaxLN/SUVaverage liver, ratio SUVmaxLN/SUVmax liver and ratio SUVmaxLN/SUVmax blood pool. A nuclear medicine physician reviewed all scans and classified nodal stations as benign or malignant.
RESULTS: Eighty-seven malignant lymph nodes and 41 benign nodes were in the prediction set. All objective FDG-PET/CT criteria analysed were significantly higher in the malignant group (P < 0.0001). EVI correctly classified 122/128 nodes (95.3%). Thirty-four malignant nodes and 19 benign nodes were in the validation set. The new proposed cut-off values of the objective criteria from the prediction set correctly classified 44/53 (83.0%) nodes: 28/34 (82.4%) malignant nodes and 16/19 (84.2%) benign nodes. EVI had 91% accuracy: 33/34 (97.1%) malignant nodes and 15/19 (79.0%) benign nodes.
CONCLUSIONS: Objective analysis of 18-F FDG PET/CT can differentiate between malignant and benign nodes but is not superior to EVI.
© 2014 Asian Pacific Society of Respirology.

Entities:  

Keywords:  lung cancer; lung cancer nodal staging; positron emission tomography; standardized uptake value criterion

Mesh:

Substances:

Year:  2014        PMID: 25263085     DOI: 10.1111/resp.12409

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  4 in total

1.  Prediction of malignant lymph nodes in NSCLC by machine-learning classifiers using EBUS-TBNA and PET/CT.

Authors:  Maja Guberina; Ken Herrmann; Christoph Pöttgen; Nika Guberina; Hubertus Hautzel; Thomas Gauler; Till Ploenes; Lale Umutlu; Axel Wetter; Dirk Theegarten; Clemens Aigner; Wilfried E E Eberhardt; Martin Metzenmacher; Marcel Wiesweg; Martin Schuler; Rüdiger Karpf-Wissel; Alina Santiago Garcia; Kaid Darwiche; Martin Stuschke
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

2.  Dual time point imaging for F18-FDG-PET/CT does not improve the accuracy of nodal staging in non-small cell lung cancer patients.

Authors:  Julian M M Rogasch; Ingo G Steffen; Sandra Riedel; Ivayla Apostolova; Heinz Wertzel; H Jost Achenbach; Ferdinand L G A Steinkrüger; Thomas Kalinski; Meinald Schultz; Jens Schreiber; Holger Amthauer; Christian Furth
Journal:  Eur Radiol       Date:  2015-11-11       Impact factor: 5.315

3.  Use quantitative parameters in spectral computed tomography for the differential diagnosis of metastatic mediastinal lymph nodes in lung cancer patients.

Authors:  Suidan Huang; Hongjia Meng; Renli Cen; Zhiwen Ni; Xiaoling Li; Sushant Suwal; Huai Chen
Journal:  J Thorac Dis       Date:  2021-08       Impact factor: 2.895

Review 4.  18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of clinically node-negative non-small cell lung cancer.

Authors:  Yusuke Takahashi; Shigeki Suzuki; Noriyuki Matsutani; Masafumi Kawamura
Journal:  Thorac Cancer       Date:  2019-01-21       Impact factor: 3.500

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.